<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肺癌前沿 | wechat-feeds</title><link>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</link><description>传递最新肺癌信息</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 14 Mar 2021 22:27:42 +0800</pubDate><image><url>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</url><title>肺癌前沿 | wechat-feeds</title><link>http://MzAwMzIwODEwNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>JTO┃肺癌转移进化轨迹</title><link>https://mp.weixin.qq.com/s/iezw2UcVdHJ_-gscVIhP9w</link><description></description><content:encoded><![CDATA[JTO┃肺癌转移进化轨迹]]></content:encoded><pubDate>Sun, 14 Mar 2021 21:39:58 +0800</pubDate></item><item><title>scDbs,“看见”不可见的P53抑癌基因/RAS致癌基因突变靶点</title><link>https://mp.weixin.qq.com/s/HnStbS1wWFlg4JdS176W2w</link><description></description><content:encoded><![CDATA[scDbs,“看见”不可见的P53抑癌基因/RAS致癌基因突变靶点]]></content:encoded><pubDate>Sat, 13 Mar 2021 19:01:36 +0800</pubDate></item><item><title>[Nat Rev Dis]重磅综述带你深入了解小细胞肺癌</title><link>https://mp.weixin.qq.com/s/7ywD0UXplimjJhXpR3HdRQ</link><description></description><content:encoded><![CDATA[[Nat Rev Dis]重磅综述带你深入了解小细胞肺癌]]></content:encoded><pubDate>Mon, 22 Feb 2021 19:12:12 +0800</pubDate></item><item><title>[JTCVS-述评] 临床IA期肺腺癌侵袭性“占卜图”</title><link>https://mp.weixin.qq.com/s/8NlKRCikKKYEhTQ19pE-DA</link><description></description><content:encoded><![CDATA[[JTCVS-述评] 临床IA期肺腺癌侵袭性“占卜图”]]></content:encoded><pubDate>Tue, 16 Feb 2021 11:59:10 +0800</pubDate></item><item><title>“太平洋的风”PACIFIC模式是否适用于驱动基因阳性III期肺癌？</title><link>https://mp.weixin.qq.com/s/0r3PEKkNpqUbNUe0Z_8fuQ</link><description></description><content:encoded><![CDATA[“太平洋的风”PACIFIC模式是否适用于驱动基因阳性III期肺癌？]]></content:encoded><pubDate>Mon, 15 Feb 2021 13:28:28 +0800</pubDate></item><item><title>CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛</title><link>https://mp.weixin.qq.com/s/EXCKX9IWemox2tWNhDm2TA</link><description></description><content:encoded><![CDATA[CheckMate 017/057的五年生存结果：Nivolumab在二线非小细胞肺癌治疗中优于多西他赛]]></content:encoded><pubDate>Sun, 14 Feb 2021 08:18:01 +0800</pubDate></item><item><title>[JCOG0804]：2cm以下磨砂玻璃成分为主肺结节楔形或肺段切除范围已足够</title><link>https://mp.weixin.qq.com/s/6cmy9IfAkPV1JpNc-ntisQ</link><description></description><content:encoded><![CDATA[[JCOG0804]：2cm以下磨砂玻璃成分为主肺结节楔形或肺段切除范围已足够]]></content:encoded><pubDate>Sat, 16 Jan 2021 17:58:50 +0800</pubDate></item><item><title>[JTCVS 2021] 肺腺癌侵袭性三维影像纹理量化模型的构建</title><link>https://mp.weixin.qq.com/s/0GP1aIgSMU37-OxwtWgT_g</link><description></description><content:encoded><![CDATA[[JTCVS 2021] 肺腺癌侵袭性三维影像纹理量化模型的构建]]></content:encoded><pubDate>Sat, 02 Jan 2021 17:55:06 +0800</pubDate></item><item><title>【CA】实体瘤新辅助治疗后重分期的现状与未来</title><link>https://mp.weixin.qq.com/s/Wf3IGKV_RpHETXx9R2k1uw</link><description></description><content:encoded><![CDATA[【CA】实体瘤新辅助治疗后重分期的现状与未来]]></content:encoded><pubDate>Mon, 07 Dec 2020 20:11:09 +0800</pubDate></item><item><title>广东省医学会肺部肿瘤学分会第二届年会</title><link>https://mp.weixin.qq.com/s/RKyiwcOArI4bg0E34ve_pQ</link><description></description><content:encoded><![CDATA[广东省医学会肺部肿瘤学分会第二届年会]]></content:encoded><pubDate>Thu, 03 Dec 2020 15:41:17 +0800</pubDate></item></channel></rss>